利培酮口服液与片剂治疗精神分裂症的回顾性分析

A retrospective study of risperidone oral solution versus risperidone tablets in treating schizophrenia

目的比较利培酮口服液与利培酮片剂治疗精神分裂症的疗效与安全性。方法回顾性分析2007年5月至2011年5月在本科室住院4 wk以上,符合CCMD-3精神分裂症诊断标准的患者共204例,其中利培酮口服液组85例,利培酮片剂组119例。比较2组患者治疗前与治疗4 wk末简明精神病评定量表、阳性症状量表、阴性症状量表、副反应量表总分以及实验室检查的差异。结果 2组治疗4 wk末简明精神病评定量表、阳性症状量表、阴性症状量表分值无显著差异(P>0.05)。利培酮口服液组副反应量表总分、心电图异常发生率以及锥体外系反应发生率明显低于利培酮片剂组(6.62±3.65 vs.7.97±4.93,16.5%Vs.28.6%,23.5%vs.40.3%,P<0.05),其余不良反应项目则未见显著差异(P>0.05)。结论利培酮口服液与利培酮片剂治疗精神分裂症效果相当,利培酮口服液的安全性优于利培酮片剂。

AIM To risperidone tablets in treating retrospectively evaluate the efficacy and safety of risperidone oral solution and schizophrenia. METHODS A total of 204 patients, who met diagnostic criteria of CCMD-3 for schizophrenia and were hospitalized in our department of psychiatry from May 2007 to May 2011, included 85 patients in risperidone oral solution group and 119 patients in risperidone tablets group. Before the treatment and at the end of the 4 th week of the treatment, all patients were assessed by Brief Psychiatric Rating Scale （BPRS）, Scale for the Assessment of Negative Symptoms （SANS）, Scale for the Assessment of Positive Symptoms （SAPS）, Treatment Emergent Symptom Scale （TESS） and laboratory tests. RESULTS There were significant differences in total scales of TESS and the rates of ECG abnormalities and extrapyramidal side effects between the risperidone oral solution group and risperidone tablets group （6.62 ± 3.65 vs. 7.97 ±4.93, 16.5% vs. 28.6%, 23.5% vs. 40.3%, P 〈 0.05） . However, there were no statistically significant differences （P 〉 0.05） in the total scales of BPRS, SANS, SAPS and other index of safety. CONCLUSION The efficacy of risperidone oral solution and risperidone tablets in treating schizophrenia was equal, but risperidone oral solution is superior to risperidone tablets on the safety.